Management conundrum in a case of renal cell cancer (RCC) on dual antiplatelet therapy (DAPT) for recently placed coronary drug-eluting stent (DES).
Rudra Prasad GhoraiSridhar PanaiyadiyanPrabhjot SinghBrusabhanu NayakPublished in: BMJ case reports (2024)
A man in his 50s presented in an emergency with breathlessness and chest discomfort. On evaluation, he was diagnosed with coronary artery disease, with more than 80% narrowing of the right coronary and left circumflex arteries. The patient underwent percutaneous coronary intervention and was started on dual antiplatelet (DAPT) therapy. After starting DAPT, the patient developed gross haematuria with a drop in haematocrit. Further evaluation revealed a left renal mass with urinary bladder clots. Because of the risk of stent thrombosis on stopping DAPT, radical nephrectomy was deferred, and the patient underwent left renal artery angioembolisation and bladder clot evacuation. On the follow-up, the patient was stable with a gradual decrease in renal mass size, and after a year, the patient underwent definitive surgery. The patient is doing well in 4 years of follow-up with no metastasis.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- coronary artery disease
- case report
- acute coronary syndrome
- st segment elevation myocardial infarction
- acute myocardial infarction
- coronary artery bypass
- st elevation myocardial infarction
- public health
- emergency department
- coronary artery
- minimally invasive
- cardiovascular disease
- squamous cell carcinoma
- young adults
- radiation therapy
- atrial fibrillation
- cardiovascular events
- cell therapy
- single cell
- heart failure
- spinal cord injury
- papillary thyroid
- left ventricular
- mesenchymal stem cells
- pulmonary embolism
- renal cell carcinoma
- aortic stenosis
- rectal cancer
- bone marrow
- transcatheter aortic valve replacement
- robot assisted
- aortic valve
- locally advanced
- clinical evaluation